Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,016 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
Caporali R, Allanore Y, Alten R, Combe B, Durez P, Iannone F, Nurmohamed MT, Lee SJ, Kwon TS, Choi JS, Park G, Yoo DH. Caporali R, et al. Among authors: park g. Expert Rev Clin Immunol. 2021 Jan;17(1):85-99. doi: 10.1080/1744666X.2020.1858803. Epub 2020 Dec 28. Expert Rev Clin Immunol. 2021. PMID: 33305638 Free article.
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.
Combe B, Allanore Y, Alten R, Caporali R, Durez P, Iannone F, Nurmohamed MT, Toumi M, Lee SJ, Kwon TS, Noh J, Park G, Yoo DH. Combe B, et al. Among authors: park g. Arthritis Res Ther. 2021 Apr 16;23(1):119. doi: 10.1186/s13075-021-02487-x. Arthritis Res Ther. 2021. PMID: 33863352 Free PMC article. Clinical Trial.
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.
Constantin A, Caporali R, Edwards CJ, Fonseca JE, Iannone F, Keystone E, Schulze-Koops H, Kwon T, Kim S, Yoon S, Kim DH, Park G, Yoo DH. Constantin A, et al. Among authors: park g. Rheumatology (Oxford). 2023 Aug 1;62(8):2838-2844. doi: 10.1093/rheumatology/keac689. Rheumatology (Oxford). 2023. PMID: 36534825 Free PMC article. Clinical Trial.
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
Kim JY, Săndulescu O, Preotescu LL, Rivera-Martínez NE, Dobryanska M, Birlutiu V, Miftode EG, Gaibu N, Caliman-Sturdza O, Florescu SA, Shi HJ, Streinu-Cercel A, Streinu-Cercel A, Lee SJ, Kim SH, Chang I, Bae YJ, Suh JH, Chung DR, Kim SJ, Kim MR, Lee SG, Park G, Eom JS. Kim JY, et al. Among authors: park g. Open Forum Infect Dis. 2022 Aug 8;9(8):ofac406. doi: 10.1093/ofid/ofac406. eCollection 2022 Aug. Open Forum Infect Dis. 2022. PMID: 36043180 Free PMC article.
4,016 results